Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
6
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
6
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
6
×
pfizer
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
cancer
gene therapy
merck
biogen
celgene
clinical trials
deals
diagnostics
gilead sciences
What
bio
roundup
drug
patients
acquisitions
biggest
ceo
moves
advantages
albert
american
annual
ash
august
bar
becker
billions
biotech
blood
borne
bourla
brings
build
busy
buy
cancers
company
company’s
conference
crispr
daniel
days
debut
decisions
devices
diego
dollars
drugs
dyne’s
eaton
Language
unset
unknown
Current search:
pfizer
×
novartis
×
" indiana blog main "
×
amgen
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More